Prophylactic Effect of Monoclonal Antibody 1D2 Administration in a Mouse Model of Invasive Aspergillosis
Journal of Fungi · 06.11.2026 · 12 (11) · 835
DOI: 10.3390/jof12110835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 06.11.2026. Verfasst von Xihua Lian und 6 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Otago Sandy Smith Scholarship/Grants-in-Aid, McGee Fellowship 2023, University of Otago Research Grant.
Abstract (Originalsprache)
Objective
To investigate the prophylactic efficacy of monoclonal antibody (mAb) 1D2 against Aspergillus fumigatus in an immunosuppressed mouse model of invasive aspergillosis (IA).
Methods
BALB/c mice (n = 18) were immunosuppressed with cyclophosphamide and randomly assigned into three groups (n = 6 each): 1D2 prophylaxis, isotype antibody (6B10) control and PBS control. Two hours prior to intravenous inoculation of A. fumigatus conidia (2 × 105 conidia per mouse), 1D2 (100 μg) or control interventions were administered intravenously. Clinical signs and body weight were monitored, and mice were euthanised for tissue and blood collection 48 h after infection. Liver injury was assessed histologically using a modified semi-quantitative scoring system. Fungal burden was assessed by colony-forming unit (CFU) counts in blood and sampled liver, spleen, kidney, and lung tissues. Plasma cytokine concentrations were analysed by ELISA.
Results
1D2-treated mice showed a lower loss of body weight post-inoculation than PBS controls (p = 0.007) and had significantly reduced clinical distress scores on days 1 and 2 (p < 0.05). Histopathological analysis showed alleviated liver injury in the 1D2 group, with a median liver injury score of 4.5 (IQR 3.0–5.25) versus 8.0 (IQR 6.75–10.0) in PBS controls (p < 0.05). CFU counts in the liver, spleen and kidney were significantly lower in the 1D2-treated group than in either control group (p < 0.05). Plasma IL-6 levels were reduced in the 1D2-treated group (582.9 ± 279.7 pg/mL) compared with PBS (1073 ± 289.1 pg/mL) and 6B10 (1080 ± 357.4 pg/mL)-treated controls (p < 0.05). TNF-α and IL-1 showed no significant differences.
Conclusions
Prophylactic administration of mAb 1D2 was associated with reduced post-inoculation weight loss, lower clinical distress scores, less liver injury, and reduced recoverable CFU counts in sampled liver, spleen and kidney tissues. Plasma IL-6 concentrations were also lower in the 1D2-treated group. These findings provide proof-of-concept evidence supporting further preclinical evaluation of 1D2 as a prophylactic candidate against IA.
Förderung
- University of Otago Sandy Smith Scholarship/Grants-in-Aid
- McGee Fellowship 2023
- University of Otago Research Grant
- Canterbury Medical Research Foundation
- Maurice and Phyllis Paykel Trust
- Joint Funds for the Innovation of Science and Technology, Fujian province
Zitieren
APA
Lian, X., Chambers, S. T., Miller, A., Drake, M., Lewis, J. G., Bhatia, M., & Scott-Thomas, A. (2026). Prophylactic Effect of Monoclonal Antibody 1D2 Administration in a Mouse Model of Invasive Aspergillosis. Journal of Fungi, 12(11), 835. https://doi.org/10.3390/jof12110835
Vancouver
Lian X, Chambers ST, Miller A, Drake M, Lewis JG, Bhatia M, et al. Prophylactic Effect of Monoclonal Antibody 1D2 Administration in a Mouse Model of Invasive Aspergillosis. Journal of Fungi. 2026;12(11):835. doi:10.3390/jof12110835
BibTeX
@article{Lian2026,
author = {Lian, Xihua and Chambers, Stephen T. and Miller, Andrew and Drake, Matthew and Lewis, John G. and Bhatia, Madhav and Scott-Thomas, Amy},
title = {Prophylactic Effect of Monoclonal Antibody 1D2 Administration in a Mouse Model of Invasive Aspergillosis},
journal = {Journal of Fungi},
year = {2026},
volume = {12},
number = {11},
pages = {835},
doi = {10.3390/jof12110835}
}
EUVIMED